Heartflow (NASDAQ:HTFL) Director Sells $228,050.00 in Stock

Heartflow, Inc. (NASDAQ:HTFL) Director Julie Cullivan sold 9,122 shares of Heartflow stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $25.00, for a total transaction of $228,050.00. Following the transaction, the director owned 27,291 shares in the company, valued at approximately $682,275. This trade represents a 25.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Heartflow Trading Down 7.6%

HTFL stock traded down $1.88 during trading on Friday, hitting $22.98. The company had a trading volume of 839,171 shares, compared to its average volume of 1,611,570. The business has a 50-day moving average of $28.43 and a 200-day moving average of $30.96. Heartflow, Inc. has a one year low of $20.13 and a one year high of $41.22. The stock has a market cap of $1.96 billion and a PE ratio of -12.70.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Wells Fargo & Company initiated coverage on Heartflow in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 target price for the company. Canaccord Genuity Group upped their price target on Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. raised their price objective on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Finally, Stifel Nicolaus upped their target price on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and an average target price of $38.50.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. XXEC Inc. raised its position in Heartflow by 40.5% in the 4th quarter. XXEC Inc. now owns 41,920 shares of the company’s stock valued at $1,222,000 after buying an additional 12,088 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Heartflow in the fourth quarter valued at about $72,000. Invesco Ltd. lifted its position in shares of Heartflow by 463.9% during the fourth quarter. Invesco Ltd. now owns 577,397 shares of the company’s stock valued at $16,831,000 after purchasing an additional 475,004 shares in the last quarter. XTX Topco Ltd boosted its holdings in Heartflow by 282.6% during the fourth quarter. XTX Topco Ltd now owns 43,205 shares of the company’s stock worth $1,259,000 after purchasing an additional 31,913 shares during the last quarter. Finally, VARCOV Co. bought a new stake in Heartflow in the 4th quarter worth about $1,657,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.